Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Versus Placebo in Uterine Myomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be a pre-menopausal woman between 18 and 50 years inclusive.~* Have excessive uterine bleeding due to myoma.~* Have a myoma-related anaemia.~* Have a myomatous uterus with at least one myoma of ≥ 3 cm diameter in size.~* Be eligible for one surgical procedure: e.g. hysterectomy, myomectomy or others.~* If of childbearing potential the subject must be practicing a non-hormonal method of contraception.~* Have a Body Mass Index (BMI) ≥ 18 and ≤ 40.~Exclusion Criteria:~* Has a history of or current uterine, cervical, ovarian or breast cancer.~* Has a history of or current endometrium atypical hyperplasia.~* Has a known severe coagulation disorder.~* Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM) or a GnRH-agonist.~* Has abnormal hepatic function at study entry.~* Has a positive pregnancy test at baseline or is nursing or planning a pregnancy during the course of the study.~* Has a current (within twelve months) problem with alcohol or drug abuse.~* Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- A (PGL4001 5mg) (Type: EXPERIMENTAL): PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
- B (PGL4001 10mg) (Type: EXPERIMENTAL): PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
- C (placebo) (Type: PLACEBO_COMPARATOR): PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+

Based on this trial design, predict the completion outcome and termination type (if applicable).